Jonathan Alicea

Patients who received ixekizumab achieved PASI 90 at a median of 43.0 days and PASI 100 at 85.0 days.

In a Q&A, Peter Lio, MD, discusses some evidence for using integrative therapies with patients.

The oral S1P receptor modulator has promise to break new ground for disease modification.

Brett King, MD, PhD, discusses new ground that that oral JAK inhibitor breaks in the alopecia areata therapeutic field.

Esther Freeman, MD, PhD, talks about the various levels of dermatologic severity associated with COVID-19.

Data also suggests the nonionic block polymer surfactant may be harmful for children <16 years of age.

The monoclonal antibody was linked to significant improvements in endoscopic nasal polyp and nasal obstruction symptom visual analogue scale scores.

Ennis James, MD, discusses the challenges and lingering questions associated with sarcoidosis

According to objective and subjective measures, children with more severe atopic dermatitis were more likely to report a learning disability.

Elevated B cell activating factor levels in children and adults were associated with the development of FVIII inhibitors, which may lead to FVIII infusion failures.

Maria DeSancho, MD, talks personal experiences with patients, vaccine hesitancy, mRNA versus adenovirus technology, risks and types of thrombosis, and more.

SDOCT imaging shows that sickle cell patients with no clinical evidence of retinopathy have considerably lower central macular thickness when compared with healthy controls.

Opioid-exposed infants diagnosed with neonatal opioid withdrawal syndrome present with various comorbidities but a prolonged survival rate.

The approval of the sBLA means greater flexibility and reduced barriers in care during the pandemic.

Initial rates of common treatment-emergent adverse events from baricitinib 2 mg appear to remain stable or decrease with prolonged exposure.

Compared with controls, children and adolescents with sickle cell anemia were more likely to be underweight and exhibit signs of stunting and wasting.

Some strains appear to reduce risk in pregnant women and infants.

Patients who received voxelotor 1500 mg achieved significant improvements in markers of hemolysis through week 72 when compared with the placebo group.

fMRI imaging shows decreased functional connectivity within the frontoparietal network of affected patients.

Some exposed newborns with negative PCR assays presented with fundus abnormalities.

A dermatologist discusses alternative and complementary options for the treatment of atopic dermatitis.

Older children seem to be at higher risk for myocarditis and pneumonia.

The non-invasive device uses air pressure pulsations to help open airways and provide clearance of secretions in patients with disease such as COPD, asthma, and cystic fibrosis.

A new study supports the potential association between hydroxyurea and improved neurocognitive performance in pediatric patients.

A dermatologist gives a broad overview of key considerations when determining a treatment course for pediatric patients.

The once-daily tablet is indicated for adult patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia

An expert offers his perspective on the investigative SLP receptor modulator for atopic dermatitis.

The Harmony Transcatheter Pulmonary Valve System is designed to treat adult and pediatric patients with pulmonary valve regurgitation.

A proposed smartphone-based intervention to address hydroxyurea nonadherence was welcomed by a majority of surveyed individuals with sickle cell disease.

A dermatologist discusses some of her most common cosmetic practices and techniques.